Menu Search
Equities

Zhejiang Medicine Co Ltd

600216:SHH

Zhejiang Medicine Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)14.94
  • Today's Change-3.62 / -19.50%
  • Shares traded29.84m
  • 1 Year change+34.72%
  • Beta0.8004
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Zhejiang Medicine Co Ltd's revenues fell -3.96% from 8.12bn to 7.79bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 539.57m to 429.64m, a -20.37% decrease.
Gross margin36.63%
Net profit margin9.46%
Operating margin11.72%
Return on assets6.57%
Return on equity9.85%
Return on investment8.36%
More ▼

Cash flow in CNYView more

In 2023, Zhejiang Medicine Co Ltd did not generate a significant amount of cash. However, the company earned 634.31m from its operations for a Cash Flow Margin of 8.14%. In addition the company used 518.59m on investing activities and also paid 141.43m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share10.75
Tangible book value per share10.01
More ▼

Balance sheet in CNYView more

Zhejiang Medicine Co Ltd has a Debt to Total Capital ratio of 6.84%, a higher figure than the previous year's 0.69%.
Current ratio2.61
Quick ratio1.78
Total debt/total equity0.0753
Total debt/total capital0.0684
More ▼

Growth rates in CNY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -11.76% and -20.08%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)2.83%
Div growth rate (5 year)0.00%
Payout ratio (TTM)14.75%
EPS growth(5 years)3.57
EPS (TTM) vs
TTM 1 year ago		178.86
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.